GoAI
Get started
Perseus Proteomics Inc. logo

Perseus Proteomics Inc.

4882.T

JPXHealthcareDrug Manufacturers - General

Open in GoAI

Latest quote

¥148

+¥1.00 · +0.68%

Aug 24, 3:30 PM JST

4882.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.

Industry
Drug Manufacturers - General
Sector
Healthcare
Headquarters
JP
CEO
Takuya Yokokawa
Listed since
Jun 22, 2021
Employees
35

Market position

Day range

Current ¥148

52-week range

Current ¥148

Open
¥147
Previous close
¥147
Volume
121.6K
0.28× average
Average volume
430.29K
Average daily volume
Market cap
2.73B JPY
Beta
0.32
Market reference 1
50-day average
¥149.62
-1.08% below average
200-day average
¥213.83
-30.78% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.76B JPY
P/E (TTM)
-3.08×
P/B (TTM)
2.07×
P/S (TTM)
18.53×
EV / EBITDA
-2.46×
Earnings yield
-21.90%
Free cash flow yield
-20.21%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
85.92%
Operating margin
-496.49%
Net margin
-505.80%
Return on equity
-58.97%
Return on assets
-44.23%
Return on invested capital
-47.81%

Financial health

Debt / equity
0×
Current ratio
24.58×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends214%-264%-742%-1219%Gross margin, FY2021: 94.18%Gross margin, FY2022: 91.86%Gross margin, FY2023: 87.33%Gross margin, FY2024: 86.44%Gross margin, FY2025: 85.73%Operating margin, FY2021: -669.44%Operating margin, FY2022: -740.72%Operating margin, FY2023: -891.37%Operating margin, FY2024: -689.26%Operating margin, FY2025: -549.75%Net margin, FY2021: -832.76%Net margin, FY2022: -835.45%Net margin, FY2023: -1100.04%Net margin, FY2024: -751.65%Net margin, FY2025: -529.94%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 94.18%. Gross margin FY2022 91.86%. Gross margin FY2023 87.33%. Gross margin FY2024 86.44%. Gross margin FY2025 85.73%. Operating margin FY2021 -669.44%. Operating margin FY2022 -740.72%. Operating margin FY2023 -891.37%. Operating margin FY2024 -689.26%. Operating margin FY2025 -549.75%. Net margin FY2021 -832.76%. Net margin FY2022 -835.45%. Net margin FY2023 -1100.04%. Net margin FY2024 -751.65%. Net margin FY2025 -529.94%.

Income trends

Revenue

135.51M JPY+12.57%

Operating income

−744.96M JPY+10.21%

Net income

−718.11M JPY+20.63%
Income trends across reported periods259.5M JPY−236.48M JPY−732.47M JPY−1.23B JPYRevenue, FY2021: 71.93M JPYRevenue, FY2022: 94.2M JPYRevenue, FY2023: 100.4M JPYRevenue, FY2024: 120.38M JPYRevenue, FY2025: 135.51M JPYOperating income, FY2021: −481.54M JPYOperating income, FY2022: −697.77M JPYOperating income, FY2023: −894.95M JPYOperating income, FY2024: −829.7M JPYOperating income, FY2025: −744.96M JPYNet income, FY2021: −599.02M JPYNet income, FY2022: −787M JPYNet income, FY2023: −1.1B JPYNet income, FY2024: −904.8M JPYNet income, FY2025: −718.11M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 71.93M JPY. Revenue FY2022 94.2M JPY. Revenue FY2023 100.4M JPY. Revenue FY2024 120.38M JPY. Revenue FY2025 135.51M JPY. Operating income FY2021 −481.54M JPY. Operating income FY2022 −697.77M JPY. Operating income FY2023 −894.95M JPY. Operating income FY2024 −829.7M JPY. Operating income FY2025 −744.96M JPY. Net income FY2021 −599.02M JPY. Net income FY2022 −787M JPY. Net income FY2023 −1.1B JPY. Net income FY2024 −904.8M JPY. Net income FY2025 −718.11M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue135.51M JPY120.38M JPY100.4M JPY94.2M JPY71.93M JPY
Cost of goods sold19.34M JPY16.32M JPY12.72M JPY7.67M JPY4.18M JPY
Gross profit116.16M JPY104.05M JPY87.69M JPY86.53M JPY67.75M JPY
Research and development573.59M JPY594.55M JPY616M JPY494.49M JPY308.42M JPY
Selling, general, and administrative287.53M JPY335.93M JPY366.41M JPY289.81M JPY231.52M JPY
Operating expenses861.12M JPY933.75M JPY982.64M JPY784.3M JPY549.29M JPY
Interest income5.04M JPY1.95M JPY46K JPY55K JPY49K JPY
Depreciation and amortization382K JPY2.85M JPY3.5M JPY5.71M JPY2.96M JPY
Operating income−744.96M JPY−829.7M JPY−894.95M JPY−697.77M JPY−481.54M JPY
Net income−718.11M JPY−904.8M JPY−1.1B JPY−787M JPY−599.02M JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-11.85

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-10.23-13.79-17.35-20.91Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual -20.11, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual -13.3, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual -14.21, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual -11.94, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual -13.78, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual -11.42, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual -11.03, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual -11.85, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates46.44M30.96M15.49M17.85KQ4 '24BeatQ1 '25No estimateQ2 '25No estimateQ3 '25No estimateQ4 '25No estimateQ1 '26No estimateQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Nov 14, 2024: actual 39M JPY, estimate 21K JPY, surprise +185614.29%, Beat. Q1 2025, reported Feb 14, 2025: actual 24M JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual 37M JPY, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual 23M JPY, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 37M JPY, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual 43M JPY, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual 32M JPY, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual 35M JPY, estimate —, surprise —, Comparison unavailable.

4882.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

-0.34%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

+0.57%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

0.00%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

+0.12%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

+0.86%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

+0.82%

Continue in GoAI

Research 4882.T

research.disclaimer